WALTHAM, Mass.– BostonGene has announced a new collaboration with the SWOG Cancer Research Network to support a nationwide clinical trial aimed at improving treatment strategies for patients with extensive-stage small cell lung cancer (ES-SCLC) through precision medicine.
The trial, named PRISM (S2409), will enroll up to 900 patients and use BostonGene’s artificial intelligence-driven multiomics platform to guide treatment decisions based on tumor subtypes. Backed by the National Cancer Institute (NCI), the randomized Phase II study will test whether combining maintenance immunotherapy with targeted therapies—such as PARP inhibitors—improves outcomes over current standard treatment.
ES-SCLC is typically treated with a combination of chemotherapy and anti-PD-L1 immunotherapy, followed by maintenance immunotherapy. This approach has shown modest survival benefits, often extending life by just two to three months. The PRISM trial aims to go further by tailoring treatment to the genetic and molecular characteristics of individual patients’ tumors.
“PRISM will test whether targeting the specific vulnerabilities of molecular subtypes can lead to better results for patients,” said study chair Dr. Anne Chiang of Yale Cancer Center. She noted that identifying subtypes in real-world clinical settings could allow oncologists to make more personalized treatment decisions.
The trial builds on earlier research from MD Anderson Cancer Center and BostonGene, which helped identify four distinct SCLC molecular subtypes. Preliminary results from a previous SWOG study (S1929) showed that subtype-guided treatment improved progression-free survival.
Researchers from MD Anderson, Yale, and Moffitt Cancer Center will lead the trial, with Drs. Chiang and Alberto Chiappori serving as clinical chairs and Drs. Lauren Byers and Carl Gay overseeing translational science.
“This is a critical step toward redefining how we treat SCLC,” said Nathan Fowler, MD, Chief Medical Officer at BostonGene. “By leveraging deep molecular profiling and AI, we aim to deliver more effective, personalized therapies and accelerate the development of future treatments.”
The study is being conducted under the NCI’s National Clinical Trials Network and could help establish a framework for biomarker-driven treatment across other types of cancer.
